AR047160A1 - Compuestos moduladores de cb1 - Google Patents

Compuestos moduladores de cb1

Info

Publication number
AR047160A1
AR047160A1 ARP040104819A ARP040104819A AR047160A1 AR 047160 A1 AR047160 A1 AR 047160A1 AR P040104819 A ARP040104819 A AR P040104819A AR P040104819 A ARP040104819 A AR P040104819A AR 047160 A1 AR047160 A1 AR 047160A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
group
compounds
formulas
Prior art date
Application number
ARP040104819A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR047160A1 publication Critical patent/AR047160A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

Se describen compuestos como moduladores del receptor de cannabinoides-1 (CB1), estos compuestos son utiles en el tratamiento, prevencion y supresion de enfermedades mediadas por el receptor CB1. Como tales, los compuestos del presente son utiles para el tratamiento, prevencion y supresion de psicosis, pérdidas de memoria, trastornos cognitivos, migrana, neuropatía, trastornos neuroinflamatorios (por ejemplo, esclerosis multiple, síndrome de Guillain-Barre y las secuelas inflamatorias de la encefalitis viral), accidentes cerebrovasculares, y traumatismo craneal, trastornos de ansiedad, estrés, epilepsias, enfermedad de Parkinson, y esquizofrenia. Los compuestos también son utiles para el tratamiento de trastornos de abuso de sustancias, particularmente de opiáceos, alcohol, y nicotina. Los compuestos también son utiles para el tratamiento de la obesidad o trastornos alimenticios asociados con una ingesta excesiva de alimentos y las complicaciones asociadas que conllevan. Reivindicacion 1: Un compuesto de formula (1), en la que el resto de formula (2) es un anillo 6,5-bicíclico seleccionado de entre el grupo de formulas (3); R1 se selecciona entre el grupo compuesto por: a) hidrogeno; b) alquilcarbonilo opcionalmente sustituido con heterociclilo; c) heterociclilcarbonilo opcionalmente sustituido con alquilo o acetilo; d) alquilo o haloalquilo; e) cicloalquilo opcionalmente sustituido con uno o dos sustituyentes seleccionados independientemente entre el grupo compuesto por alquilo, halo, oxo, hidroxi, alcoxi, amino, alquilamino y dialquilamino; f) heterociclilo seleccionado entre los compuestos del grupo de formulas (4); g) arilo opcionalmente sustituido con halo, alquilo, alcoxi ciano, amino, alquilamino o dialquilamino; y h) heteroarilo seleccionado entre los compuestos del grupo de formulas (5); R2 es hidrogeno, alquilo, heterociclilo o, junto con R1 y el carbono a los que están unidos, forma un sustituyente de anillo saturado seleccionado entre el grupo compuesto por: a) cicloalquilo; y b) heterociclilo seleccionado entre el grupo compuesto por tetrahidrofuranilo, tetrahidropiranilo y piperidinilo opcionalmente N-sustituido con alquilo, acetilo o arilo, X es -NR13R3 o un compuesto de formula (6); R3 se selecciona entre el grupo compuesto por: a) hidrogeno; b) alquilo opcionalmente sustituido con uno o dos sustituyentes seleccionados independientemente entre el grupo compuesto por hidroxi, alcoxi, halogeno, amino, alquilamino y dialquilamino; c) cicloalquilo opcionalmente sustituido con uno o dos sustituyentes seleccionados independientemente entre el grupo compuesto por hidroxi, alcoxi, halo, amino, alquilamino y dialquilamino; d) heterociclilo seleccionado entre los compuestos del grupo de formulas (7); e) cicloalquilalquilo seleccionado entre los compuestos del grupo de formulas (8); f) heterociclilalquilo seleccionado entre los compuestos del grupo de formulas (9); g) arilalquilo seleccionado entre los compuestos del grupo de formulas (10); h) heteroarilalquilo seleccionado entre los compuestos del grupo de formulas (11); y el compuesto de formula (6) es un anillo heterocíclico seleccionado entre los compuestos del grupo de formulas (12); R4 es hidrogeno, fenilo, halofenilo, acilo o alcoxicarbonilo; R5 es hidrogeno, hidroxi o alcoxi; cada uno de R6 y R7 se selecciona independientemente entre hidrogeno, halo, ciano, alquilo, alcoxi, haloalquilo, haloalcoxi, amino, alquilamino, dialquilamino, alcoxicarbonilo, dialquilaminocarbonilo, arilo y ariloxi; R8 es hidrogeno, hidroxialquilo, acilo, oxo, arilo, piridinilo, alquil-SO2-O-, Rb-NH-CH2-, arilalquilo o Rc2N-CO-O-; R9 es hidrogeno, hidroxi, hidroxialquilo, acilo, halo, dihalo, oxo, arilo, haloaril-CH2-, piridinilo, alquil-SO2-O-, Ra-NH-, Rb-NH-CH2, arilalquilo, el compuesto de formula (13) o Rc2N-CO-O-; R10 es hidrogeno, alquilo, alcoxicarbonilo, arilo o haloarilo; R11 es hidrogeno, alquilo o arilo; R12 es hidrogeno o arilo; R13 es hidrogeno o alquilo; R14 es hidrogeno, alquilo, arilo o acilo; Ra es hidrogeno, alcoxicarbonilo o halofenilo; Rb es hidrogeno, alcoxi, fenilo, halofenilo, halofenilalquilo, halopiridinilo, pirimidinilo, alcoxicarbonilo, dialquilaminocarbonilo o dialquilaminotiocarbonilo; y Rc es hidrogeno o alquilo; y todas las sales, solvatos, isomeros opticos y geométricos y formas cristalinas de los mismos con la condicion de que el compuesto de formula (1) es diferente de [4- (2,3-dihidro-indol-1-sulfonil)-fenil]-(4-fenil-piperazin-1-il)-metanona, [4-(2,3-dihidro-indol-1-sulfonil)-fenil]-morfolin-4-il-metanona y [4-(2,3-dihidro-indol-1-sulfonil)-fenil]-piperidin-1-il-metanona.
ARP040104819A 2003-12-23 2004-12-21 Compuestos moduladores de cb1 AR047160A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53224703P 2003-12-23 2003-12-23

Publications (1)

Publication Number Publication Date
AR047160A1 true AR047160A1 (es) 2006-01-11

Family

ID=34748790

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104819A AR047160A1 (es) 2003-12-23 2004-12-21 Compuestos moduladores de cb1

Country Status (17)

Country Link
US (2) US7276516B2 (es)
EP (1) EP1699761B1 (es)
JP (1) JP2007519631A (es)
AR (1) AR047160A1 (es)
AT (1) ATE502009T1 (es)
AU (1) AU2004312311A1 (es)
BR (1) BRPI0418079A (es)
CA (1) CA2549396A1 (es)
DE (1) DE602004031875D1 (es)
ES (1) ES2360112T3 (es)
IL (1) IL176069A0 (es)
NO (1) NO20063381L (es)
PE (1) PE20050598A1 (es)
SV (1) SV2005001984A (es)
TW (1) TW200522944A (es)
WO (1) WO2005066126A1 (es)
ZA (1) ZA200605159B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
WO2004056363A2 (en) 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
GB0516379D0 (en) * 2005-08-09 2005-09-14 Glaxo Group Ltd Compounds
US7544676B2 (en) * 2005-11-10 2009-06-09 Adolor Corporation Sulfamoyl benzamides and methods of their use
FR2893615B1 (fr) * 2005-11-18 2008-03-07 Sanofi Aventis Sa Derives de 3-acylindole, leur preparation et leur application en therapeutique
MX2008010481A (es) 2006-02-17 2008-12-19 Memory Pharm Corp Compuestos que tienen afinado para el receptor f-ht6.
EP1998748B1 (en) 2006-03-16 2015-01-14 NicoNovum AB Improved snuff composition
WO2007138611A1 (en) * 2006-05-30 2007-12-06 Suven Life Sciences Limited 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands
US9079854B2 (en) 2007-07-13 2015-07-14 The Cleveland Clinic Foundation Hydrazone modulators of cannabinoid receptors
WO2009012227A1 (en) * 2007-07-13 2009-01-22 Board Of Regents, The University Of Texas System Hydrazone modulators of cannabinoid receptors
US7759335B2 (en) * 2008-01-31 2010-07-20 Jenrm Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
US20100056491A1 (en) * 2008-08-29 2010-03-04 Memory Pharmaceuticals Corporation 4'-amino cyclic compounds having 5-ht6 receptor affinity
WO2010032257A1 (en) * 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
NZ597379A (en) 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
WO2011094545A2 (en) 2010-01-28 2011-08-04 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8796258B2 (en) 2011-02-25 2014-08-05 Merck Sharp & Dohme Corp. Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2699577A1 (en) 2011-04-20 2014-02-26 Glaxo Group Limited Tetrahydropyrazolo [1,5 -a]pyrimidine as anti -tuberculosis compounds
CN103635230B (zh) 2011-05-12 2017-10-31 普罗蒂斯特斯治疗公司 蛋白内稳态调节剂
KR20140112075A (ko) * 2012-01-16 2014-09-22 바이엘 인텔렉쳐 프로퍼티 게엠베하 고나도트로핀-방출 호르몬 수용체 길항제로서의 스피로인돌린 유도체
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
TW201410243A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療***素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410244A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
RU2582393C2 (ru) * 2013-07-31 2016-04-27 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения ожирения и сопутствующих метаболических расстройств
RU2557971C2 (ru) * 2013-07-31 2015-07-27 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ воздействия на функциональную активность каннабиноидного рецептора
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
EP3145925B1 (en) * 2014-05-19 2020-11-04 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds
RU2016149804A (ru) * 2014-05-23 2018-06-26 Ф. Хоффманн-Ля Рош Аг Производные бензолсульфонамида и их применение в качестве модуляторов орфанного рецептора y, связанного с ретиноевой кислотой
JP2019511580A (ja) 2016-04-15 2019-04-25 エスアールイー ウェルネス インク．Ｓｒｅ Ｗｅｌｌｎｅｓｓ Ｉｎｃ． 乳化剤を使用して***油を親水性にする方法及び関連するカンナビノイド組成物
JP7053054B2 (ja) 2016-04-15 2022-04-12 エスアールイー ウェルネス，インク． ***注入甘味料及び他の組成物
CN106349196B (zh) * 2016-08-26 2019-01-04 江苏克胜作物科技有限公司 一种呋虫胺的合成方法
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
WO2018210658A1 (en) * 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
AU2019391109A1 (en) * 2018-12-07 2021-06-24 Opiant Pharmaceuticals, Inc. Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
CN113861194B (zh) * 2021-11-10 2022-07-05 英维沃化工科技(广州)有限公司 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用
WO2023235305A2 (en) * 2022-05-31 2023-12-07 Lysoway Therapeutics, Inc. Sulfonyl cyclic derivatives, and compositions and methods thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5081122A (en) 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
US4973587A (en) 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
AU1618697A (en) 1996-02-06 1997-08-28 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
ES2213892T3 (es) 1997-01-21 2004-09-01 Smithkline Beecham Corporation Nuevos moduladores del receptor de canabinoides.
DK0966436T3 (da) 1997-02-21 2003-03-31 Bayer Ag Arylsulfonamider og analoger deraf og anvendelse deraf til behandling af neurodegenerative lidelser
WO1998041519A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761265B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
KR20010021696A (ko) 1997-07-11 2001-03-15 미즈노 마사루 퀴놀린 화합물 및 그의 의약용도
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
AU1179000A (en) * 1998-11-19 2000-06-13 Shionogi & Co., Ltd. Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
US6566356B2 (en) 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
EA006132B1 (ru) * 2000-10-20 2005-10-27 Биовитрум Аб 2-, 3-, 4- или 5-замещенные n-(1-(арил-, гетероарил- или арилалкил)сульфонил)индолы и их применение в терапии
CA2432825A1 (en) * 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
WO2003026648A1 (en) 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
ATE504568T1 (de) 2003-08-07 2011-04-15 Nat Health Research Institutes Indol-verbindungen als inhibitoren der tubulin- polymerisation zur behandlung von angiogenesisbezogenen erkrankungen

Also Published As

Publication number Publication date
SV2005001984A (es) 2005-11-04
US7595339B2 (en) 2009-09-29
EP1699761A1 (en) 2006-09-13
NO20063381L (no) 2006-09-20
AU2004312311A1 (en) 2005-07-21
CA2549396A1 (en) 2005-07-21
US20080287504A1 (en) 2008-11-20
ZA200605159B (en) 2007-12-27
EP1699761B1 (en) 2011-03-16
IL176069A0 (en) 2006-10-05
DE602004031875D1 (de) 2011-04-28
BRPI0418079A (pt) 2007-04-17
US20070088018A1 (en) 2007-04-19
TW200522944A (en) 2005-07-16
ATE502009T1 (de) 2011-04-15
ES2360112T3 (es) 2011-06-01
WO2005066126A1 (en) 2005-07-21
US7276516B2 (en) 2007-10-02
PE20050598A1 (es) 2005-08-15
JP2007519631A (ja) 2007-07-19

Similar Documents

Publication Publication Date Title
AR047160A1 (es) Compuestos moduladores de cb1
JP2007519631A5 (es)
HRP20191469T1 (hr) Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinase
JP5736507B2 (ja) 含窒素複素環化合物またはその塩
RU2011140064A (ru) Ингибиторы тирозинкиназы брутона
RU2338742C2 (ru) Производные индола, способ их получения (варианты), промежуточные соединения, используемые для их получения, фармацевтическая композиция содержащая их и их применение для лечения состояний, связанных с гликоген-синтазой-киназой-3
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR038834A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco
AR038420A1 (es) Compuesto de amida, procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
JP2018507877A5 (es)
CO5680434A2 (es) 2,4-pirimidinadiaminas utiles en el tratamiento de enfermedades neoplasticas, desordenes del sistema inmune e inflamatorios
ES2579830T3 (es) Derivados de diaminopirimidina y procedimientos para la preparación de los mismos
CA2570197A1 (en) Nk1 antagonists
AR046186A1 (es) Compuestos derivados de 1,3,8-triaza-espiro[4.5]decan-4-ona
AR062209A1 (es) Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos.
RS53108B (en) AMINO-1,3,5-TRIAZINES N-REPLACED BY CHIRAL BICYCLIC RADICALS, THE PROCESS FOR THEIR PREPARATION, THEIR COMPOUNDS AND THEIR APPLICATIONS AS HERBICIDES AND PLANT GROWTH REGULATORS
PT1618092E (pt) Compostos de pirazol-amida substituídos com arilo úteis enquanto inibidores de cinase
AR050281A1 (es) Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas
AR049951A1 (es) Derivados de ftalazina como inhibidores de parp
AR049521A1 (es) Derivados de pirrazol - pirimidina
PE20161443A1 (es) Compuestos
MX2020005874A (es) Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa).
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
RU2009103307A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure